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COMMENTARY Open Access
A randomised controlled trial is not a pilot
trial simply because it uses a surrogate
endpoint
M. J. Campbell1* , G. A. Lancaster2 and S. M. Eldridge3
Abstract
Background: It has been argued that true endpoints (or ‘hard’ endpoints) for clinical trials, which are meaningful
to clinicians, researchers and patients alike, are limited to those that measure health status, survival and cost. Other
endpoints are termed 'surrogate' endpoints and are intended to substitute and predict the true endpoint. A number
of trials that describe using surrogate endpoints use the term ‘pilot’ in the title of the paper but the reason for this, as
related by the authors, is the use of these surrogate endpoints in the trial. The conduct and reporting of such a trial
may follow the traditional pattern for a conventional randomised controlled trial (RCT) as defined by the original
CONSORT statement, with power-based sample size calculations, and significance tests of the results. However, this is
contrary to the guidelines of the CONSORT extension for the reporting of pilot trials.
Main body: We review the definition of a surrogate endpoint and the use of surrogate endpoints in clinical trials. We
consider to what extent a trial could be considered a pilot trial if it uses a surrogate endpoint and discuss two
examples that illustrate current practice.
Conclusion: Trials which use surrogate endpoints should only be described as ‘pilot’ when a definitive trial is a
distinct possibility and the authors consider conditions which would indicate whether the definitive main trial
was worthwhile and feasible. Simply because a trial uses a surrogate endpoint is not justification for calling it a
pilot trial.
Keywords: Pilot trials, Surrogate endpoints, Randomised controlled trials, CONSORT
Background
The recent discussion on pilot studies has come up with
a clear picture of what a pilot trial should be and how it
should be conducted and reported [1–3]. Here, the focus
should be on preparation for a future definitive trial with
feasibility objectives that address uncertainties in the study
design. However, trials that use surrogate endpoints have
also been described as ‘pilot trials’, and yet these may not
differ from a main trial testing effectiveness in any other
way, other than the endpoint used. This paper discusses to
what extent the use of surrogate endpoints can justify the
description of a trial as a pilot trial.
Surrogate endpoints
Weintraub et al. [4] have argued that the true endpoints
for randomised controlled trials (RCTs), those which are
meaningful to clinicians, researchers and patients alike,
are limited to health status, survival and cost. Sometimes,
these are termed ‘hard’ endpoints. All other measures may
then be seen as what are known as ‘surrogate’ endpoints.
They also have argued that even serious events such as
myocardial infarction and stroke may be considered surro-
gates, as their effect is to adversely affect the critical end-
points of health status, survival, and cost. Contentiously,
this would mean that most clinical trials are run with
surrogate endpoints. However, the reason for choosing a
surrogate endpoint is that often it is difficult to run trials
with true endpoints. Thus, surrogates have to be variables
that are good predictors of the true endpoints. For
example, high blood pressure is usually symptom-less and
so does not affect health status, but it is highly correlated
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with events such as strokes and death and is a commonly
used surrogate [4].
A surrogate is a relatively easy-to-measure endpoint
which is available over a reasonably short time-frame
that is used in place of the true endpoint. Surrogates are
‘Biomarker or intermediate end point intended to substi-
tute and predict for patient-relevant final end point’ [5].
Surrogates are usually continuous variables which will
allow for much smaller sample sizes than dichotomous
variables as well as shorter periods of follow-up and lower
costs. Thus, compared with clinical endpoint trials, studies
with surrogate endpoints can be conducted rapidly and
with much less resource use and expense than true
endpoint studies.
Recent studies have challenged the assumption that
reliance on surrogates can accurately predict the effect
of treatment on clinical or true outcomes. The classic
example is a study of type-I anti-arrhythmic drugs in
patients who had heart rhythm disturbances after myocar-
dial infarction. Among these patients, a trial showed that the
anti-arrhythmic drugs encainide and flecainide decreased
electrocardiographic (ECG) instances of arrhythmia, which
was the surrogate end point. For this reason, these drugs
were used regularly for this type of patient. When tested in
an RCT with hard endpoints, however, patients who took
encainide and flecainide turned out to be more than twice
as likely to die from cardiac arrest or other causes than those
randomised to placebo [6]. In effect, the drugs reduced
arrhythmia but killed people. Other examples include oral
hypoglycaemic drugs that reduce HbA1c but increase the
risk of cardiovascular events [7]; antihypertensive drugs that
do not reduce the risk of stroke [8]; and drugs that improve
cholesterol profiles but do not reduce cardiovascular events
[9]. Kemp and Prasad [10] showed that between 2004 and
2008, 36 oncology drugs were approved on the basis of a
surrogate endpoint (such as progression free survival). With
a median follow-up of 4.4 years, only 5 (14%) had been
shown to give an improvement in overall survival (a ‘hard’
endpoint) in a randomised controlled trial.
Pilot trials are trials done before a main trial, designed
to support the development of a future definitive RCT
[1]. ‘Definitive’ in this context means an appropriately
powered study focusing on effectiveness or efficacy. A
definitive trial could still use a surrogate endpoint,
provided that endpoint has been rigorously assessed as
being an effective substitute for a hard endpoint. However,
there is still no clear consensus. The question is whether
trials done using surrogate endpoints can be considered
‘pilots’? Two relevant points in the recent CONSORT ex-
tension to pilot trials are that ‘the number of participants
in a pilot study should be based on the feasibility objec-
tives’ and ‘formal hypothesis testing for effectiveness (or
efficacy) is not recommended’ [2, 3]. The aim of a pilot
trial should be not to assess effectiveness (or efficacy) of a
treatment, but rather to decide whether a larger definitive
trial is worthwhile and feasible [2, 3].
Examples
An example of a trial that is described as a pilot trial
and uses a surrogate endpoint is that of Krarup et al.
[11]. They describe the ExSTroke Pilot trial, to examine
the benefits of exercise in patients who have had a
stroke. They intended to recruit 300 subjects, but this
was powered on a postulated difference in treatment
groups from a surrogate endpoint, the Physical Activity
Scale for the Elderly (PACE). The reason for the term
‘pilot’ in the title could be inferred because the study
was not powered for recurrent stroke, myocardial infarc-
tion, or mortality, which may be regarded as hard end-
points. The results were published as a randomised
controlled trial using conventional tests of significance
although the word ‘pilot’ was retained in the title [12].
The authors admit that the study was not powered to
show an effect of physical training on recurrent stroke,
acute myocardial infarction, or survival, which would
have needed more than ten times the sample size. How-
ever, to be consistent with the CONSORT extension, the
trial should only deserve the label ‘pilot’ if there were
clear criteria to decide on whether to conduct a subse-
quent trial using clinically meaningful outcomes, and a
clear intention of conducting such a trial if the criteria
were met. Otherwise, the title should simple state that
the study is a randomised controlled trial that uses
surrogate end points. Thus, if the ExStroke trial was to
be regarded as a pilot, it could have specified what size
difference in the PACE outcome would have justified
further follow up for stroke and death.
The DECADE trial protocol gives another example of
the use of surrogate endpoint in a pilot trial [13]. In this
case one of the endpoints is the score for the 10-year
risk of cardiovascular disease. However, here the authors
do not power the study on a change in the risk score
and rather state their objective is to find out whether the
DECADE intervention is promising and whether a larger
multi-centre randomised controlled trial is feasible. Their
objectives were: to test DECADE regarding its usability
and acceptance in primary care; to test the feasibility of
the randomised study design; to generate initial data on
the potential effects of DECADE in terms of patient
knowledge, skills, confidence and behaviour critical for
coping with a chronic illness, behavioural changes and
clinical outcomes. This study thus falls within the scope of
the definition of a pilot trial [1].
Discussion
How a study is described, particularly in a title, is import-
ant because it influences how the paper describing the
study is retrieved, and also suggests how the study should
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be analysed and reported. Thus, a trial which is described
as a ‘pilot’ trial leads to the expectation that it is preparatory
to a definitive trial, and the main reporting would be to
enable the reader to decide whether a definitive trial was
worthwhile and feasible. There is often an implicit assump-
tion that a trial using a surrogate endpoint should be
followed by a definitive trial, and so could be regarded
as a pilot. However, if the surrogate has been previously
rigorously assessed as a valid substitute for a hard endpoint,
and the investigators are willing to discontinue or not
recommend the new treatment based on the results of this
trial, a further trial with hard endpoints is unnecessary. If,
on the other hand, the surrogate endpoint has not been
rigorously evaluated previously and part of the current
study is devoted to choosing a suitable endpoint in a
subsequent main trial, then the study may reasonably
be described as a pilot. There is still much discussion
about the best methods to validate surrogate endpoints
[14]. We do not believe that studies to validate a surrogate
endpoint should be described as pilot studies either. Such
a study could be part of a large scale cohort study, and
not related to any particular treatment.
A related issue is that of phase II, or ‘proof of concept’
drug trials. These form part of a drug development
programme and may well be followed by a phase III drug
trial if the sponsor thinks the results look promising.
These may use surrogate endpoints but are not usually
described as ‘pilot’ trials and so are not part of this
commentary.
In reviewing the evidence for this commentary, we
have found there are few surrogates that can be used
with confidence as a substitute for a hard endpoint and
it is rare for trials (except Phase II drug trials) which use
surrogate endpoints to be followed by trials using defini-
tive endpoints. Surrogate endpoints on average give larger
effect sizes [15]. Many reported RCTS use surrogates and
in fact more than 40% of pivotal trials used as the basis
for approval of new indications used a surrogate as the
primary endpoint [5]. As a general reporting issue,
trials that use surrogate endpoints should clearly explain
that the endpoints are surrogates, and if possible should
report how these endpoints were validated so that they
could be used with confidence as substitutes for hard
endpoints.
Conclusions
For the reasons outlined in this commentary, we believe
that the use of the word ‘pilot’ to describe a study that
uses a surrogate endpoint, but in all other respects is a
conventional RCT, should be discouraged.
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